ArticleEuropean radiology2018
Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients.
Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2020Guideline
- Abdominopelvic Preoperative Imaging in Adult Candidates for Kidney Transplant: A Systematic Review of Its Impact on Surgical Decision-making.European urology open science · 2026Review
- Abdominal vascular imaging with ferumoxytol - how we do it.Pediatric radiology · 2026Review
- Selective use of ferumoxytol-enhanced magnetic resonance angiography in patients with renal insufficiency: insights from a pilot study.The international journal of cardiovascular imaging · 2026Article
- Comparison of three diagnostic imaging modalities for use in diabetic inferior arterial lesions.World journal of diabetes · 2025Article
- Ferumoxytol-enhanced cardiovascular magnetic resonance imaging: applications and technical advances.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2025Review
- The use of ferumoxytol for high-resolution vascular imaging and troubleshooting for abdominal allografts.Abdominal radiology (New York) · 2024Review
- Peripheral Arterial Disease: A Narrative Review.Cureus · 2023Review
- Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.AJR. American journal of roentgenology · 2023Article
- Nano-embedded medical devices and delivery systems in interventional radiology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Article
- Article
- Nanotechnology in Kidney and Islet Transplantation: An Ongoing, Promising Field.Frontiers in immunology · 2022Review
- One-pot synthesis of carboxymethyl-dextran coated iron oxide nanoparticles (CION) for preclinical fMRI and MRA applications.NeuroImage · 2021Article
- Alternative Diagnostic Strategy for the Assessment and Treatment of Pulmonary Embolus: A Case Series.Clinical practice and cases in emergency medicine · 2020Article
- Two Non-gadolinium-based, Innovative Approaches to Preoperative Lymphangiography.Plastic and reconstructive surgery. Global open · 2020Article
- Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.European radiology · 2019Article
- Noncontrast MR angiography: An update.Journal of magnetic resonance imaging : JMRI · 2019Review
- A Case of Ferumoxytol (FerahemeJournal of clinical imaging science · 2019Article
- Ferumoxytol-enhanced MRI in the peripheral vasculature.Clinical radiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTraditional contrast-enhanced methods for scanning blood vessels using magnetic resonance imaging (MRI) or CT carry potential risks for patients with advanced kidney disease. Ferumoxytol is a superparamagnetic iron oxide nanoparticle preparation that has potential as an MRI contrast agent in assessing the vasculature.
methodsTwenty patients with advanced kidney disease requiring aorto-iliac vascular imaging as part of pre-operative kidney transplant candidacy assessment underwent ferumoxytol-enhanced magnetic resonance angiography (FeMRA) between December 2015 and August 2016. All scans were performed for clinical indications where standard imaging techniques were deemed potentially harmful or inconclusive. Image quality was evaluated for both arterial and venous compartments.
resultsFirst-pass and steady-state FeMRA using incremental doses of up to 4 mg/kg body weight of ferumoxytol as intravenous contrast agent for vascular enhancement was performed. Good arterial and venous enhancements were achieved, and FeMRA was not limited by calcification in assessing the arterial lumen. The scans were diagnostic and all patients completed their studies without adverse events.
conclusionsOur preliminary experience supports the feasibility and utility of FeMRA for vascular imaging in patients with advanced kidney disease due for transplant listing, which has the advantages of obtaining both arteriography and venography using a single test without nephrotoxicity. KEY POINTS: • Evaluation of vascular disease is important in planning kidney transplantation. • Standard vascular imaging methods are often problematic in kidney disease patients. • FeMRA has the advantage of arteriography and venography in a single test. • FeMRA is safe and non-nephrotoxic. • FeMRA is not limited by arterial calcification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.